Introduction {#s1}
============

Gene expression is central to variety of fundamental cellular processes that governs the growth and proliferation in mammalian cell. It is a highly regulated process that is governed by transcription factors and their co-regulators in the target gene chromatin [@pone.0017135-Auboeuf1]--[@pone.0017135-Lonard2]. Co-regulators are emerging transcription factor (TF) family that stringently controls the actions of almost "all" nuclear receptors (NRs) through direct binding to NRs rather than binding to DNA [@pone.0017135-Auboeuf1]--[@pone.0017135-McKenna1]. Recent literature highlights the significance of coregulators in induction or repression of gene transcription [@pone.0017135-Collingwood1], [@pone.0017135-Martini1]. In fact, the coregulators either function as enzymes that are essential for gene expression or they regulate other coregulators through diverse mechanisms [@pone.0017135-Martini1]--[@pone.0017135-Pan1]. There has been a tremendous focus on understanding the molecular mechanism of coregulators due to their crucial regulatory role in almost "all" TF-dependent gene expression and nuclear receptors dependent functions in several tissues such as breast, ovary, prostate, gastrointestinal, pancreatic and lungs [@pone.0017135-Collingwood1], [@pone.0017135-Dobrzycka1], [@pone.0017135-Hsia1]. More interestingly, many cancers over express "growth coactivators" that allow the cancer cell to hijack these molecules which consequently results in rapid proliferation, malignant process and rapid metastasis.

One emerging group of chromatin modifiers and coregulators is the metastasis-associated protein (MTA) family. This family comprises three different known genes (*MTA1*, *MTA2*, and *MTA3*) and is an integral part of the NuRD (Nucleosome Remodeling and Histone Deacetylation) complex that has indispensable transcriptional regulatory functions via histone deacetylation and chromatin remodeling [@pone.0017135-Manavathi1], [@pone.0017135-Denslow1]. MTA1, the founding member of the MTA family was initially identified through differential screening of a cDNA library from rat metastatic breast tumors as an upregulated gene [@pone.0017135-Toh1], [@pone.0017135-Toh2]. Subsequent studies found MTA1 to be widely up-regulated in various human cancers and established to be involved in tumorigenesis, tumor invasion, and metastasis [@pone.0017135-Manavathi1], [@pone.0017135-Kumar1]. Owing to its name as a coregualtor the repressor function of MTA1 is observed through its direct interaction with ERα [@pone.0017135-Mazumdar1] and HDACs which represses estrogen-responsive element (ERE) transactivation activity in a HDAC-sensitive manner that promotes the development of hormone-independent growth of breast cancer cells. In addition, MTA1-NuRD complex was also reported to negatively regulate BRCA1 transcription by physically associating with an atypical estrogen-responsive element (ERE) on the BRCA1 promoter [@pone.0017135-Molli1]. The transcription activator function of MTA1 is evident from reports showing the stimulation of breast cancer-amplified sequence 3 (BCAS3) [@pone.0017135-Gururaj1] and paired box gene 5 (Pax 5) [@pone.0017135-Balasenthil1] promoters mainly through the interaction with RNA polymerase II. It is noteworthy that the MTA family members exist in distinct NuRD complexes, and functional redundancy is lacking among MTA family members [@pone.0017135-Yao1].

Further, recent studies from this laboratory have discovered for the first time that MTA1 is a bona-fide DNA-damage responsive protein due to the induction of intracellular levels of MTA1 by ionizing radiation (IR) and an integral component of DNA damage response and contributes to double-strand DNA break repair [@pone.0017135-Li1]. One of the main DNA damage responsive mechanisms employed by MTA1 is through direct interaction and controlling the stability of P53 [@pone.0017135-Li2]. P53 is a well-studied tumor suppressor protein which plays a central role in preserving the genomic integrity in response to DNA damage, through inhibiting its ubiquitination by E3 ubiquitin ligases, mouse double minute 2 (Mdm2) and constitutive photomorphogenic protein 1 (COP1), thereby regulating the P53-dependent DNA repair [@pone.0017135-Levine1]--[@pone.0017135-Wang1]. Interestingly, these events could be reversed by MTA1 reintroduction, indicating that MTA1 interjects into the P53-dependent DNA repair [@pone.0017135-Li2]. This identified interplay between oncogene (MTA1) and tumor suppressor (P53) exemplifies the highly complex check point mediated "failsafe mechanism" that controls the mitogenic signaling. Moreover, studies from our laboratory illustrated the participation of MTA1 in a P53-independent DNA damage response. MTA1-histone deacetylase 2 (HDAC2) complexes recruit P53-independent transcriptional corepressor, p21WAF1 [@pone.0017135-elDeiry1], [@pone.0017135-Harper1] onto two selective regions of the p21WAF1 promoter which increases p21WAF1 binding to proliferating cell nuclear antigen (PCNA). This decreases the nuclear accumulation of PCNA in response to ionizing radiation [@pone.0017135-Li3]. MTA1 is also shown to be stabilized by UV radiation in ATR (Ataxia teleangiectasia and Rad3-related) kinase dependent manner and there is a subsequent increase in MTA1 binding to ATR. However, depletion of MTA1 compromises the ATR-mediated Chk1 activation following UV treatment. Consequently, expression of MTA1 in P53-null cells results in increased induction of histone, γH2AX [@pone.0017135-Li4] foci and DNA double strand break repair and decreased DNA damage sensitivity following ionizing radiation treatment. These early studies linking the MTA/NuRD complexes to DNA-damage response were further supported by more recent reports showing the recruitment of the NuRD complexes to the site of DNA damage [@pone.0017135-Smeenk1], [@pone.0017135-Chou1] Together, the P53-independent role of MTA1 in DNA damage response connects NuRD complex and DNA-damage response pathways [@pone.0017135-Li5].

To further characterize the potential mechanism for the functional role of MTA1 in DNA repair, we performed a complete gene profiling study to identify differences between the *MTA1* ^+/+^ and *MTA1* ^−/−^ mouse embryonic fibroblasts (MEFs) in the presence and absence of P53, using Affymetrix Mouse Exon 1.0 ST arrays. The comparative gene profiling of *Mta1* wild type, *Mta1* knock out and *Mta1* knockout in which *Mta1* was reintroduced conditions define "bona fide" Mta1 target genes such as *Egr2*, *Phf17*, and *Aw551984*. In depth analyses of the microarray data of all five samples that include the above three along with *P53* knockout and *P53* knockout with *Mta1* over expression clearly indicates influence of *P53* on *Mta1* gene regulation. Mta1 target genes are mostly involved in inflammatory and anti-microbial responses in the presence of P53 whereas the predominant target genes and functions identified appear to be related to cancer signaling in the absence of P53. Thus, we provide a complete gene profiling of *Mta1* which not only emphasizes the known functions of Mta1 but also acts as a guide to identify novel functions.

Results {#s2}
=======

Strategy to identify the possible target genes of MTA1 in a P53 dependent and independent manner {#s2a}
------------------------------------------------------------------------------------------------

The aim of the study is to identify the genes that are regulated by *Mta1* in P53 dependent and independent manners. The detailed schematic of the strategy followed to identify the genes is shown in [Figure 1](#pone-0017135-g001){ref-type="fig"}. Murine Embryonic Fibroblasts (MEFs) from wild type, *Mta1* knockout [@pone.0017135-Manavathi2] and *P53* knockout mice embryos [@pone.0017135-McMasters1] were isolated and cultured to obtain five different types of samples, each in triplicates, for the identification of the genes that are regulated by *Mta1* with/without the *P53* background. The sample sets are as follows: 1) *Mta1*-Wildtype (WT), 2) *Mta1*-knockout (*Mta1*-KO) [@pone.0017135-Li1], 3) *Mta1* transfected into the *Mta1*-knock out MEFs (*Mta1*-KO/*Mta1*), 4) *P53*-Knock (*P53*-KO) and 5) *Mta1* over expressed in the *P53*-Knockout MEFs (*P53*-KO/*Mta1*) [@pone.0017135-Li3]. The protein levels of Mta1 in all the five samples are compared using Western blot probed with Mta1 antibody ([Figure S1](#pone.0017135.s001){ref-type="supplementary-material"}). Total RNA was isolated from the MEFs, cDNA was prepared, processed and hybridized onto Affymetrix Mouse Exon 1.0 ST arrays. The gene expression data from all the samples were obtained, quality control steps were performed and the data was analyzed using GeneSpring GX 10.0.2 (Agilent Technologies).

![Schematic showing the experimental design of the study to identify the *Mta1* regulated genes with/without the effect of *P53*.\
RNA was extracted from all the samples Wild Type (WT), *Mta1* knock out (*Mta1-*KO), *Mta1* Re-expression in the *Mta1* knock out MEFS (*Mta1*-KO/*Mta1*), P53 knock out (*P53*-KO), *Mta1* over expression (OE) in the *P53* knock out MEFs ( *P53*-KO/*Mta1*). cDNA was prepared, processed and hybridized onto the Affymetrix Mouse Exon 1.0 ST arrays followed by the data analysis. Samples were compared to identify the differentially regulated genes and in turn the genes regulated by *Mta1* in *p53* dependent/independent manner and irrespective of *P53* status. Candidate genes were selected; these genes were validated using RT-qPCR assays in MEFs followed by RT-qPCR assays in MCF-7 human breast cancer cell line with the human homologs of the candidate mouse genes.](pone.0017135.g001){#pone-0017135-g001}

Genes regulated by *Mta1* under different conditions were identified by performing gene expression analysis followed by the Gene Ontology analysis. Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Inc) was used to identify top 15 statistically significant functions of the differentially regulated genes and top 15 canonical pathways in which these genes could play a role. Candidate genes were selected based upon the functions and our laboratory interests. RT-qPCR assays were performed to validate the microarray gene regulation of the selected candidate genes. The differential regulation of the candidate genes was confirmed using MEFs and the MCF7 human breast cancer cell line for the respective human homologs. Using this strategy, we have identified a set of genes which, we believe, are regulated by *Mta1* in *P53* dependent and independent manners, thus, providing overall gene profiling of *Mta1*.

Quality Control and Gene Expression Analysis {#s2b}
--------------------------------------------

We generated cDNAs from the total RNA of the corresponding MEFs and three biological replicates for each sample were hybridized. The raw data was obtained and normalized log2 ratio values were used to identify the differential gene expression levels across different samples. The quality control of all the samples and the replicates was analyzed by unsupervised Principle Component Analysis (PCA) method in which each of the samples, in a different color, was plotted in three dimensional (3D) space with components 1, 2 & 4 along X, Y & Z axes respectively. [Figure 2](#pone-0017135-g002){ref-type="fig"} shows the PCA-plot with replicates of each sample clustered close to each other illustrating the similarity between the sample replicates. We performed unpaired t-test with a p-value less than 0.05 and Benjamini Hochberg false discovery rate (FDR) was applied for the multiple corrections to filter the false positives so that the statistically significant genes could be obtained.

![Principle Component Analysis as a quality control.\
All the sample sets (each in triplicates) were plotted in the 3-D PCA-plot. Out of the 4 total PCA components, components 1, 2 & 4 were plotted on columns X, Y & Z respectively.](pone.0017135.g002){#pone-0017135-g002}

Genes regulated by *Mta1* in the presence of *P53* in MEFs {#s2c}
----------------------------------------------------------

The initial comparison between the *Mta1* wild type, the *Mta1* knock out and *Mta1*-re-expression in knockout MEFs was performed. Although differential expression of the genes between *Mta1* wild type and *Mta1* knock out was reported by us earlier [@pone.0017135-Li3], our aim of this study is to identify the genes differentially regulated among *Mta1* wild type, *Mta1* knock out and *Mta1*-KO in which *Mta1* WT was reintroduced. Therefore, we have used the data from Li et al, (2010) for comparison. When *Mta1* WT and knockout conditions were compared, 1124 genes were reported with a fold change ≥±2.0 and with the p-value\<0.05. These 1124 genes were either directly or indirectly regulated by *Mta1*. Top 25 differentially expressed Affymetrix probes are shown in [Table 1](#pone-0017135-t001){ref-type="table"} (complete list is shown in [Table S1](#pone.0017135.s002){ref-type="supplementary-material"}, statistically summary is shown in [Table S2](#pone.0017135.s003){ref-type="supplementary-material"}). It is noteworthy that a gene encoding epidermal growth factor-containing fibulin-like extra cellular matrix protein 1 (*EFEMP1*) is identified to be up-regulated by 100 fold with the highest fold change regulation in the *Mta1* knockout MEFs when compared with the wild type *Mta1* MEFs. Interestingly, Sadr-Nabavi et al., (2009) reported a reduction in RNA and protein levels of EFEMP1 in human sporadic breast cancer tissues [@pone.0017135-SadrNabavi1] which imply that over expression of *Mta1* could lead to down regulation of *EFEMP*. In addition, we also found that the gene encoding CD24/HSA had the maximum fold change among the down regulated genes. CD24 is a cell adhesion molecule that is expressed on the surface of the infected cells [@pone.0017135-Ali1].

10.1371/journal.pone.0017135.t001

###### Top 25 differentially expressed Affymetrix Mouse Exon 1.0 St Array probe sets in MEFs between the wild type and *Mta1* knock out.

![](pone.0017135.t001){#pone-0017135-t001-1}

  refseq           Gene Symbol       FC     Reg                                   Gene Description
  -------------- ---------------- -------- ------ --------------------------------------------------------------------------------
  NM_146015          *Efemp1*      100.24    up    epidermal growth factor-containing fibulin-like extracellular matrix protein 1
  NM_009099          *Trim30*      79.45     up                            tripartite motif-containing 30
  NM_133871          *Ifi44*       79.08     up                            interferon-induced protein 44
  NM_009252        *Serpina3n*     72.25     up             serine (or cysteine) peptidase inhibitor, clade A, member 3N
  NM_008331          *Ifit1*       71.62     up             interferon-induced protein with tetratricopeptide repeats 1
  NM_015784          *Postn*       49.40     up                        periostin, osteoblast specific factor
  NM_009846          *Cd24a*       47.95    down                     CD24a antigen \| predicted gene, EG621324
  NM_134086         *Slc38a1*      42.67    down                         solute carrier family 38, member 1
  NM_001033767      *EG240327*     41.75     up                               predicted gene, EG240327
  NM_001111059        *Cd34*       40.98    down                                    CD34 antigen
  NM_011409          *Slfn3*       34.62     up                                      schlafen 3
  NM_001085522    *RP24-320O9.1*   32.71     up                          novel KRAB box containing protein
  NM_010681          *Lama4*       30.71     up                                   laminin, alpha 4
  NM_007833           *Dcn*        30.43     up                                       decorin
  NM_009251        *Serpina3g*     30.43     up             serine (or cysteine) peptidase inhibitor, clade A, member 3G
  NM_023386           *Rtp4*       28.17     up                            receptor transporter protein 4
  NM_010917           *Nid1*       27.87     up                         nidogen 1 \| similar to Nid1 protein
  NM_008409          *Itm2a*       26.76     up                             integral membrane protein 2A
  NM_011854          *Oasl2*       26.58     up                        2′-5′ oligoadenylate synthetase-like 2
  NM_008489           *Lbp*        26.45     up                          lipopolysaccharide binding protein
  NM_019955          *Ripk3*       25.19     up                    receptor-interacting serine-threonine kinase 3
  NM_025711           *Aspn*       23.86     up                                       asporin
  NM_025949         *Rps6ka6*      23.80    down                     ribosomal protein S6 kinase polypeptide 6
  NM_025961           *Gatm*       23.37    down         glycine amidinotransferase (L-arginine:glycine amidinotransferase)
  NM_001001892      *EG630499*     23.27     up                          histocompatibility 2, K1, K region

Top 25 probe sets with fold change of 2.0 or more and FDR less than 0.05 are shown. Wild type cells are the control against the knock out cells as treatment.

When *Mta1* was transfected into the *Mta1* knock-out MEFs and compared against the *Mta1*-KO, 184 differentially regulated genes were identified. The top 25 differentially regulated genes based upon fold change are shown in [Table 2](#pone-0017135-t002){ref-type="table"} (the entire list is shown in [Table S3](#pone.0017135.s004){ref-type="supplementary-material"} and statistical summary in [Table S4](#pone.0017135.s005){ref-type="supplementary-material"}). Out of these 184 genes, 126 genes were found to be present in WT Vs *Mta1-*KO as well (1124 genes, [Figure 3A](#pone-0017135-g003){ref-type="fig"} top panel). Majority of these 126 genes appear to restore their functioning when *Mta1* is transfected back into the *Mta1* knock out cells. Among these 126 genes except 6 genes, rest of them regained their expression levels similar to WT. Therefore these represent "bona fide" *Mta1* target genes ([Table 3](#pone-0017135-t003){ref-type="table"} and [Table S5](#pone.0017135.s006){ref-type="supplementary-material"}). Since *P53* is present in all the three samples they reflect the number of genes influenced by *MTA1* in the presence of *P53*.

![Genes regulated by *Mta1*in the presence and absence of *P53*.\
**A**: Venn diagrams showing the number of genes that are identified to be genuinely regulated by *Mta1* in the presence and absence of *P53*. (i) The genes shown in WT vs. *Mta1*-KO (1124) are the genes affected by *Mta1* knock out and the genes that are present in *Mta1-*KO vs. *Mta1-*KO*/Mta1* (184) are affected due to re-expression of *Mta1* in the knockout MEFs. The genes that are differentially regulated in both the sets with opposite trends in the regulation are considered as the 'bona fide' genes regulated by *Mta1*. ii) Similarly, the intersection of *P53*-KO and *P53*-KO/*Mta1* represents the genes differentially regulated by *Mta1* over expression in the *P53-*KO MEFs. i.e. the genes regulated by *Mta1* in the absence of *P53*.This scenario of *Mta1* over expression and *P53* knock out/mutation mimics most of the cancers iii) The Venn diagram between genes regulated by *Mta1* in the presence of *P53*, *126* and genes regulated by *Mta1* in the absence of *P53*, *266* gives the genes that are regulated by *Mta1* only in the presence of *P53*, irrespective of *P53* status and only in the absence of *P53* respectively. **B**: Heat maps representing hierarchical clustering of the differentially regulation, plotted using the log2 values of the genes with p-value≤0.05 (unpaired t-test) and with fold change of at least 2 between the comparisons *Mta1* knock out vs. *Mta1* knock out/*Mta1* and *P53* knock out vs. *P53* knock out/Mta1. Each column represents a sample plotted in triplicates and each row in the heat map represents a gene that is differentially regulated in that particular comparison of samples. The color scale represents the degree of expression of the gene, green being the lowly expressed (below −3.0) and red being (above +3.0) the highly expressed genes in the sample sets with black as the center of the scale at '0'. **C**: Pie diagrams showing the percentage of up-regulated and the down-regulated genes in each sample comparison. The red segment of the pie represents the up-regulated genes whereas; the green segments represent the down regulated genes.](pone.0017135.g003){#pone-0017135-g003}

10.1371/journal.pone.0017135.t002

###### Top 25 differentially expressed Affymetrix Mouse Exon 1.0 St Array probe sets in MEFs between the *Mta1* knock out and *Mta1* knock out/*Mta1*.

![](pone.0017135.t002){#pone-0017135-t002-2}

  refseq          Gene Symbol    FC     Reg                                        Gene Description
  -------------- ------------- ------- ------ ------------------------------------------------------------------------------------------
  NM_134066        *Akr1c18*    14.98    up                            aldo-keto reductase family 1, member C18
  NM_025711         *Aspn*      9.58    down                                           asporin
  NM_029803         *Ifi27*     8.86    down                            interferon, alpha-inducible protein 27
  NM_178737       *AW551984*    6.75    down                             Mouse homolog of human gene *VWA5A*
  NM_007621         *Cbr2*      6.01    down                                     carbonyl reductase 2
  NM_011595         *Timp3*     5.67     up                            tissue inhibitor of metalloproteinase 3
  NM_027495        *Tmem144*    5.13     up                                   transmembrane protein 144
  NM_029000         *Gvin1*     4.89    down                          GTPase, very large interferon inducible 1
  NM_013585         *Psmb9*     4.53    down   proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)
  NM_028608        *Glipr1*     4.36    down                             GLI pathogenesis-related 1 (glioma)
  NM_023422       *Hist1h2bc*   3.91    down                                      histone cluster 1
  NM_001097644     *Ccnyl1*     3.91    down                                       cyclin Y-like 1
  NM_008630          *Mt2*      3.78     up                                       metallothionein 2
  NM_008604          *Mme*      3.78    down                                membrane metallo endopeptidase
  NM_008728         *Npr3*      3.74     up                                 natriuretic peptide receptor 3
  NM_009251       *Serpina3g*   3.73    down                 serine (or cysteine) peptidase inhibitor, clade A, member 3G
  NM_011979         *Vnn3*      3.68    down                                           vanin 3
  NM_007817        *Cyp2f2*     3.65    down                    cytochrome P450, family 2, subfamily f, polypeptide 2
  NM_008185         *Gstt1*     3.64    down                              glutathione S-transferase, theta 1
  NM_054077         *Prelp*     3.58    down                        proline arginine-rich end leucine-rich repeat
  NM_053078       *D0H4S114*    3.57    down                                  DNA segment, human D4S114
  NM_011579         *Tgtp*      3.50    down                                    T-cell specific GTPase
  NM_012043         *Islr*      3.45    down                  immunoglobulin superfamily containing leucine-rich repeat
  NM_009846         *Cd24a*     3.32     up                                         CD24a antigen
  NM_133903         *Spon2*     3.26    down                           spondin 2, extracellular matrix protein

Top 25 probe sets with fold change of 2.0 or more and FDR less than 0.05 are shown. *Mta1* knock out cells are the controls and Mta1-KO/Mta1 is the treatment.

10.1371/journal.pone.0017135.t003

###### Bona fide *Mta1* regulated genes in the presence of *P53* identified from the Affymetrix Mouse Exon 1.0 ST Arrays.

![](pone.0017135.t003){#pone-0017135-t003-3}

  Gene Symbol                                   WT vs. *Mta1*-KO   *Mta1*-KO vs. *Mta1*-KO/*Mta1*         
  -------------------------------------------- ------------------ -------------------------------- ------ ------
  Cd24a                                              47.95                      down                3.32    up
  Iigp1[\*](#nt103){ref-type="table-fn"}             41.75                       up                 3.23   down
  Serpina3g[\*](#nt103){ref-type="table-fn"}         30.43                       up                 3.73   down
  Lbp[\*](#nt103){ref-type="table-fn"}               26.45                       up                 2.51   down
  Aspn[\*](#nt103){ref-type="table-fn"}              23.86                       up                 9.58   down
  Ifit3                                              22.29                       up                 2.25   down
  Apod                                               20.15                       up                 2.89   down
  Irgb10                                             18.67                       up                 2.2    down
  Ccnyl1                                             18.12                       up                 3.91   down
  Apol9a                                             17.31                       up                 2.37   down
  Apol9b[\*](#nt103){ref-type="table-fn"}            17.31                       up                 2.37   down
  Oas1a                                              15.93                       up                 2.19   down
  Zbp1                                               13.03                       up                 3.15   down
  Smpdl3b                                            12.92                      down                2.26    up
  Islr[\*](#nt103){ref-type="table-fn"}              12.85                       up                 3.45   down
  Steap4[\*](#nt103){ref-type="table-fn"}            12.37                       up                 2.55   down
  Pcdhb9                                             12.31                       up                 2.22   down
  Timp3                                              12.03                      down                5.67    up
  Ifi27                                              11.75                       up                 8.86   down
  Irf7                                               11.17                       up                 2.04   down
  Prelp[\*](#nt103){ref-type="table-fn"}             11.12                       up                 3.58   down
  Psmb9                                              11.05                       up                 4.53   down
  AW551984                                           11.04                       up                 6.75   down
  Pcdhb8                                              9.98                       up                 2.82   down
  Tspan13                                             9.95                       up                 2.03   down
  Il1rn                                               9.87                       up                 2.34   down
  Gvin1                                               9.87                       up                 4.89   down
  Lpl                                                 9.54                       up                 2.36   down
  Il1rl1[\*](#nt103){ref-type="table-fn"}             9.08                       up                 2.32    up
  Oas2                                                8.78                       up                 2.98   down
  Trim12                                              8.32                       up                 2.04   down
  Adam23                                              8.32                       up                 2.74   down
  Ednra                                               8.06                       up                  2     down
  A4galt[\*](#nt103){ref-type="table-fn"}             7.21                       up                 2.85   down
  Tap1                                                 7                         up                 2.89   down
  Ened                                                6.88                       up                 2.31    up
  Vnn3                                                6.81                       up                 3.68   down
  Dhx58                                               6.49                       up                 2.26   down
  Mgp                                                 6.29                       up                 2.64   down
  Ces1                                                6.14                       up                 2.9    down
  Slc16a4                                             5.97                       up                  3     down

\*Genes (32) regulated by *Mta1* irrespective of *P53* status. [Figure 3A](#pone-0017135-g003){ref-type="fig"} (lower panel).

Note: Continued in [Table S5](#pone.0017135.s006){ref-type="supplementary-material"}.

Genes regulated by *Mta1* in a *P53-*independent manner {#s2d}
-------------------------------------------------------

Here we identified the genes that are regulated by *Mta1* in a *P53-*independent manner. Differential gene expression analysis was performed by comparing the *P53* knock out cells and *P53* knock out/*Mta1* over expressed cells [@pone.0017135-Li3]. All the genes with *p*-value\<0.05 and fold change expression ≥±2.0 were considered as statistically significant. The statistical analysis of the data generated a set of 266 genes, top 25 differentially regulated genes are shown in [Table 4](#pone-0017135-t004){ref-type="table"} (entire list is shown in [Table S6](#pone.0017135.s007){ref-type="supplementary-material"} and statistical summary in [Table S7](#pone.0017135.s008){ref-type="supplementary-material"}) and the Venn diagram in [Figure 3A](#pone-0017135-g003){ref-type="fig"} middle panel shows the number of genes differentially regulated. When Bona fide *Mta1* regulated genes (126) were compared with *p53* independent regulated genes of *Mta1*, 32 genes were shown to be regulated by *Mta1* irrespective of *p53* status ([Figure 3A](#pone-0017135-g003){ref-type="fig"} lower panel, these genes are marked with asterisks in [Table 3](#pone-0017135-t003){ref-type="table"} and [Table S5](#pone.0017135.s006){ref-type="supplementary-material"}). Since, both the samples are *P53-*knockout MEFs, with one of them carrying over expression of *Mta1*; the differentially expressed genes were regulated by *Mta1* independent of *P53*.

10.1371/journal.pone.0017135.t004

###### Top 25 differentially expressed Affymetrix Mouse Exon 1.0 St Array probe sets between the *P53* knock out MEFs and the *P53* knock out MEFs in which *Mta1* is over expressed.

![](pone.0017135.t004){#pone-0017135-t004-4}

  refseq           Gene Symbol      FC     Reg                                  Gene Description
  -------------- ---------------- ------- ------ ------------------------------------------------------------------------------
  NM_008489           *Lbp*        26.89   down                        lipopolysaccharide binding protein
  NM_015784          *Postn*       14.70   down                      periostin, osteoblast specific factor
  NM_008607          *Mmp13*       13.37   down                            matrix metallopeptidase 13
  NM_008760           *Ogn*        12.46   down                                   osteoglycin
  NM_011339          *Cxcl15*      12.39   down                        chemokine (C-X-C motif) ligand 15
  NM_008491           *Lcn2*       9.68    down                                   lipocalin 2
  NM_001014423       *Abi3bp*      9.31    down                 ABI gene family, member 3 (NESH) binding protein
  NM_199468          *Zcchc5*      7.85    down                      zinc finger, CCHC domain containing 5
  NM_011704           *Vnn1*       7.22    down                                     vanin 1
  NM_009373           *Tgm2*       7.22    down                        transglutaminase 2, C polypeptide
  NM_054098          *Steap4*      7.06    down                              STEAP family member 4
  NM_011315           *Saa3*       6.70    down                                serum amyloid A 3
  NM_010582          *Itih2*       6.51    down                   inter-alpha trypsin inhibitor, heavy chain 2
  NM_009144          *Sfrp2*       6.46    down                       secreted frizzled-related protein 2
  NM_010809           *Mmp3*       6.39    down                            matrix metallopeptidase 3
  NM_008728           *Npr3*       5.80    down                          natriuretic peptide receptor 3
  NM_172463          *Sned1*       5.70    down                      sushi, nidogen and EGF-like domains 1
  NM_022814          *Svep1*       5.62    down    sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1
  NM_007621           *Cbr2*       5.55    down                               carbonyl reductase 2
  NM_009251        *Serpina3g*     5.53    down           serine (or cysteine) peptidase inhibitor, clade A, member 3G
  NM_025711           *Aspn*       5.47    down                                     asporin
  NM_144938           *C1s*        5.23    down                      complement component 1, s subcomponent
  NM_031167          *Il1rn*       5.15    down                        interleukin 1 receptor antagonist
  NR_001592           *H19*        5.14    down  
  NM_030601       *Clca2\|Clca1*   4.83    down   chloride channel calcium activated 2 \| chloride channel calcium activated 1

Top 25 probe sets with fold change of 2.0 or more and FDR less than 0.05 are shown. *P53-*KO is considered as the control and *P53*-KO/*Mta1* is considered as the treatment.

Hierarchical clustering analysis reveals influence of P53 on MTA1 gene regulation {#s2e}
---------------------------------------------------------------------------------

Further, we performed the hierarchical clustering analysis with the genes that were differentially regulated between the *Mta1*-KO vs. *Mta1*-KO/*Mta1*, and *P53*-KO vs. *P53*-KO/*Mta1*. The normalized log2 ratio values of the differentially regulated genes in each comparison were used to obtain the heat maps ([Figure 3B](#pone-0017135-g003){ref-type="fig"}). The gene leaf nodes were optimized in the heat maps representing the differential regulation of the genes between the samples. Color scale of the heat map depicts red as the highly expressed, green as low expressed and black as intermittent level of gene expression. [Figure 3B](#pone-0017135-g003){ref-type="fig"} shows the heat maps of all the comparisons, *Mta1*-KO with *Mta1*-KO/*Mta1* and *P53*-KO with *P53*-KO/*Mta1* representing the differential expression of the genes. We found that 64% of the differentially regulated genes were up-regulated in WT vs. *Mta1*-KO where as it greatly reduced to 30% in *Mta1*-KO vs. *Mta1*-KO/*Mta1* followed by further reduction to 22% in *P53*-KO vs. *P53*-KO/*Mta1*. In the case of differentially regulated genes that were down regulated, the percentage of down regulated genes was 36% in WT vs. *Mta1*-KO, 70% in *Mta1*-KO vs. *Mta1*-KO/*Mta1*and 78% in *P53*-KO vs. *P53*-KO/*Mta1*. In summary, we observe 78% of genes down regulated by *Mta1* due to the absence of P53 whereas about 64% of *Mta1* regulated genes were up regulated in the presence of *P53* ([Figure 3C](#pone-0017135-g003){ref-type="fig"}).

Gene Ontology analysis shows the genes involved in cellular functions regulated by *Mta1* in the presence/absence of *P53* {#s2f}
--------------------------------------------------------------------------------------------------------------------------

To further investigate the functions of the genes regulated by *Mta1*, we performed Gene Ontology (GO) analysis on all the sets of genes that are regulated by *Mta1* with/without *P53* background with a *p*-value cutoff set to 0.1. The possible functions of the gene sets were broadly classified, in GO program, into three categories namely i) Cellular Component ii) Molecular Function and iii) Biological Process. We found that the 40.23% of the differentially regulated genes in the comparison of WT vs. *Mta1*-KO, with *p*-value: 0.1617 related to molecular function, followed by 34.97% with *p*-value 0.148 connected to Cellular Component and 24.79% of the genes with *p*-value 0.0944 were associated with the biological process ([Figure 4A](#pone-0017135-g004){ref-type="fig"}). In contrast to the above, when *Mta1*-KO and *Mta1*-KO with reintroduced *Mta1* were compared there were no genes that match the GO terms in the Molecular functioning, whereas majority of them (77.78%, *p-*value: 0.6994) were related to the cellular component ([Figure 4B](#pone-0017135-g004){ref-type="fig"}). With the corrected *p*-value cut off 0.1 and in the presence of P53, *Mta1* doesn\'t regulate any genes responsible for molecular functioning. The majority of the genes (78.12%) are associated with Cellular Component and 21.88% are associated to Biological Process ([Figure 4C](#pone-0017135-g004){ref-type="fig"}). In contrast to the above, in. the absence of *P53*, 49.8% (*p*-value: 0.1212) differentially expressed genes were linked to the Cellular Component, 30.61% (*p*-value: 0.1777) to Molecular Function and 19.59% (*p*-value: 0.1253) related to Biological Process ([Figure 4D](#pone-0017135-g004){ref-type="fig"}). Tables with GO terms for all the above mentioned comparisons are shown in [Table 5](#pone-0017135-t005){ref-type="table"}, [6](#pone-0017135-t006){ref-type="table"}, [7](#pone-0017135-t007){ref-type="table"} and [8](#pone-0017135-t008){ref-type="table"} respectively. [Table 5](#pone-0017135-t005){ref-type="table"} and [Table 8](#pone-0017135-t008){ref-type="table"} are continued as [Tables S8](#pone.0017135.s009){ref-type="supplementary-material"} and [S9](#pone.0017135.s010){ref-type="supplementary-material"} respectively.

![Gene Ontology (GO) analysis of was performed using Gene Spring GX 10.0.2 (Agilent technologies Inc and Strand Life Sciences Pvt Ltd).\
With the gene set comparisons that were described in the [figure 3A](#pone-0017135-g003){ref-type="fig"} GO analysis was performed. Pie chart A shows the statistically significant (P\<0.1) differentially regulated genes between wild type and *Mta1-*KO samples matching with three broad GO terms (Cellular components, Biological process and Molecular Function), Pie chart B (*Mta1-*KO and *Mta1*-KO/*Mta1*) shows the GO terms matching with the differentially regulated genes in this comparison. Pie chart C and pie chart D show the same for bona fide *Mta1* regulated genes in the presence of *P53* (126) and *P53*-KO vs. *P53*-KO/*Mta1* (genes regulated by *Mta1* in the absence of *P53*,*266*) respectively.](pone.0017135.g004){#pone-0017135-g004}

10.1371/journal.pone.0017135.t005

###### GO Analysis of the genes differentially regulated between the WT & *Mta1*-KO with ≥2.0 fold change.

![](pone.0017135.t005){#pone-0017135-t005-5}

  GO ACCESSION                 GO Term                 p-value    Corrected p-value   Count in Selection   \% Count in Selection   Count in Total   \% Count in Total
  -------------- ------------------------------------ ---------- ------------------- -------------------- ----------------------- ---------------- -------------------
  GO:0005576             extracellular region          1.87E-27       4.82E-22               286                   44.83                2627              14.72
  GO:0044421          extracellular region part        2.27E-25       2.92E-20               244                   38.24                2157              12.08
  GO:0005615             extracellular space           2.75E-23       2.36E-18               229                   35.89                2038              11.42
  GO:0007155                cell adhesion              2.10E-17       1.08E-12                78                   12.23                541               3.03
  GO:0022610             biological adhesion           2.10E-17       1.08E-12                78                   12.23                541               3.03
  GO:0006955               immune response             1.17E-14       5.02E-10                59                   9.25                 405               2.27
  GO:0031012             extracellular matrix          9.71E-14       3.57E-09                50                   7.84                 279               1.56
  GO:0005578      proteinaceous extracellular matrix   2.06E-13       6.64E-09                49                   7.68                 275               1.54
  GO:0005488                   binding                 2.37E-13       6.80E-09               446                   69.91               10687              59.87
  GO:0005515               protein binding             7.79E-12       2.01E-07               325                   50.94                5094              28.54
  GO:0002376            immune system process          8.35E-11       1.96E-06                59                   9.25                 658               3.69
  GO:0009653      anatomical structure morphogenesis   4.52E-09       9.71E-05                28                   4.39                 1002              5.61
  GO:0005509             calcium ion binding           5.37E-09       9.89E-05                88                   13.79                791               4.43
  GO:0032502            developmental process          5.06E-09       9.89E-05                84                   13.17                2682              15.03
  GO:0048513              organ development            7.10E-09       1.14E-04                28                   4.39                 1339              7.50

Note: Continued in [Table S8](#pone.0017135.s009){ref-type="supplementary-material"}.

10.1371/journal.pone.0017135.t006

###### GO Analysis of the genes differentially regulated between the *Mta1*-KO and *Mta1*- KO/Mta1 probes with ≥2.0 fold change.

![](pone.0017135.t006){#pone-0017135-t006-6}

  GO ACCESSION             GO Term            p-value    corrected p-value   Count in Selection   \% Count in Selection   Count in Total   \% Count in Total
  -------------- --------------------------- ---------- ------------------- -------------------- ----------------------- ---------------- -------------------
  GO:0044421      extracellular region part   2.56E-12         0.00                  53                   72.60              2157.00             12.08
  GO:0005615         extracellular space      1.18E-11         0.00                  53                   72.60              2038.00             11.42
  GO:0005576        extracellular region      2.18E-11         0.00                  61                   83.56              2627.00             14.72
  GO:0006955           immune response        1.01E-07         0.01                  16                   21.92               405.00             2.27
  GO:0022610         biological adhesion      6.43E-06         0.28                  15                   20.55               541.00             3.03
  GO:0007155            cell adhesion         6.43E-06         0.28                  15                   20.55               541.00             3.03

10.1371/journal.pone.0017135.t007

###### GO Analysis of the bona fide *Mta1* regulated genes in the presence of *P53* with ≥2.0 fold change.

![](pone.0017135.t007){#pone-0017135-t007-7}

  GO ACCESSION             GO Term            p-value    corrected p-value   Count in Selection   \% Count in Selection   Count in Total   \% Count in Total
  -------------- --------------------------- ---------- ------------------- -------------------- ----------------------- ---------------- -------------------
  GO:0044421      extracellular region part   2.30E-12       2.97E-07                43                   78.18                2157              12.08
  GO:0005615         extracellular space      1.48E-12       2.97E-07                43                   78.18                2038              11.42
  GO:0005576        extracellular region      8.02E-12       6.89E-07                48                   87.27                2627              14.72
  GO:0006955           immune response        8.12E-08        0.0052                 13                   23.64                405               2.27

10.1371/journal.pone.0017135.t008

###### GO Analysis of the bona fide *Mta1* regulated genes in the absence of *P53* with ≥2.0 fold change.

![](pone.0017135.t008){#pone-0017135-t008-8}

  GO ACCESSION                            GO Term                            p-value    corrected p-value   Count in Selection   %Count in Selection   Count in Total   \% Count in Total
  -------------- ---------------------------------------------------------- ---------- ------------------- -------------------- --------------------- ---------------- -------------------
  GO:0005576                        extracellular region                     8.45E-38       2.18E-32               122                  89.05               2627              14.72
  GO:0044421                     extracellular region part                   7.08E-29       9.12E-24                99                  72.26               2157              12.08
  GO:0005615                        extracellular space                      2.37E-23       2.03E-18                88                  64.23               2038              11.42
  GO:0005578                 proteinaceous extracellular matrix              1.84E-15       1.19E-10                27                  19.71               275               1.54
  GO:0031012                        extracellular matrix                     2.64E-15       1.36E-10                27                  19.71               279               1.56
  GO:0006954                       inflammatory response                     3.07E-08      0.00131978               7                   5.11                204               1.14
  GO:0007155                           cell adhesion                         1.83E-07      0.00522946               21                  15.33               541               3.03
  GO:0022610                        biological adhesion                      1.83E-07      0.00522946               21                  15.33               541               3.03
  GO:0005509                        calcium ion binding                      7.26E-07       0.0170145               30                  21.90               791               4.43
  GO:0009605                   response to external stimulus                 6.98E-07       0.0170145               7                   5.11                465               2.61
  GO:0044268         multicellular organismal protein metabolic process      1.99E-06       0.0264874               5                   3.65                 16               0.09
  GO:0004714      transmembrane receptor protein tyrosine kinase activity    2.05E-06       0.0264874               7                   5.11                 61               0.34
  GO:0030574                     collagen catabolic process                  1.99E-06       0.0264874               5                   3.65                 16               0.09
  GO:0008237                     metallopeptidase activity                   1.68E-06       0.0264874               12                  8.76                181               1.01
  GO:0044259      multicellular organismal macromolecule metabolic process   1.99E-06       0.0264874               5                   3.65                 16               0.09

Note: Continued in [Table S9](#pone.0017135.s010){ref-type="supplementary-material"}.

Ingenuity Pathways Analysis highlights the critical role of Mta1 in cancer signaling in the presence/absence of *P53* {#s2g}
---------------------------------------------------------------------------------------------------------------------

Ingenuity pathways analysis was performed on all the genes that were identified to be regulated by *Mta1* with/without *P53*. With *p*-value\<0.05, Fischer\'s exact test was applied and we found top 15 significant functions and canonical pathways in which the genes regulated by *Mta1* might play a significant role. The most likely functions of the genes regulated by *Mta1* in the presence of *P53* are Inflammatory Response followed by Cancer and Gastrointestinal Diseases ([Figure 5](#pone-0017135-g005){ref-type="fig"} upper panel). Top 15 canonical pathways of these genes were identified with the *p*-value\<0.05 and threshold value of log (*p*-value): 0.05. The significant pathways which include LXR/RXR activation, Interferon signaling, Antigen presentation pathway and Activation of IRF by cytosolic pattern Recognition Receptors were shown in [Figure 5](#pone-0017135-g005){ref-type="fig"} (lower panel). From these observations we propose that *Mta1* might have critical functional role in orphan nuclear receptor activation, inflammation and infections. Similarly, top 15 plausible functions of the genes regulated by *Mta1* in the absence of *P53* were identified and shown in [Figure 6](#pone-0017135-g006){ref-type="fig"} (upper panel). The most significant function of the genes was found to be related to 'Cancer' followed by 'Cellular Movement' and 'Connective Tissue Disorders'. The top 15 canonical pathways in which the genes might be involved were identified and shown in the [Figure 6](#pone-0017135-g006){ref-type="fig"} (lower panel). The most significant canonical pathway identified is 'Acute Phase response Signaling' followed by Colorectal Cancer Metastasis Signaling, Hepatic fibrosis and 'Bladder Cancer Signaling'. Clearly the genes regulated by *Mta1* in the absence of *P53* highlight the typical oncogenic character of *Mta1* and its possible major role in several cancers and oncogenic signaling pathways.

![Ingenuity Pathway Analysis (Ingenuity Systems, Inc) of the genes that were regulated by *Mta1* in the presence of *P53* was performed.\
The significance of each function or canonical pathway is determined based upon the *p-*values determined using Right tailed Fisher\'s exact test and with threshold less than 0.05. The top 15 possible functions and canonical pathways of the genes regulated by *Mta1* in *P53* dependent manner are shown. Ratio of number of genes in a given pathway satisfying the cutoff and total number of genes present in that pathway was determined by IPA.](pone.0017135.g005){#pone-0017135-g005}

![Ingenuity Pathway Analysis (Ingenuity Systems, Inc) of the genes that were regulated by *Mta1* in the absence of *P53* was performed.\
Fisher\'s exact test was used and threshold of 0.05 was set as the cutoff. Top 15 functions associated with the genes and the top 15 canonical pathways in which these genes might have a role are shown.](pone.0017135.g006){#pone-0017135-g006}

The identified *Mta1* regulated candidate genes and their human homologs follow similar expression profile in MEFs and human breast cancer cell lines {#s2h}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Based upon our analysis and our laboratory interest, some of the genes that were regulated by *Mta1* with/without *P53* back ground were selected for the validation using the RT-qPCR assays. Validations were first performed in the MEFs followed by the MCF7 human breast cancer cell line. The results showing relative mRNA levels, for the selected genes, are presented in [Figure 7](#pone-0017135-g007){ref-type="fig"}. The controls are compared with the treatments and if the trend of expression (up or down regulation) in qPCR is in agreement with the microarray gene expression, then the respective homologous genes were selected for further validation in the human breast cancer cell line (MCF7). *Aw551984* gene is the homolog of the human gene *VWA5A*, also known as BCSC-1. Monaco et al (1997) characterized and proposed that this gene could be a tumor suppressor [@pone.0017135-Monaco1], [@pone.0017135-Gentile1]. We found that both *Aw551984*/*VWA5A* were negatively regulated by *Mta1 in* MEFs and human breast cancer cells. In the case of *VWA5A*, the expression trend is similar in MEFs and MCF7 cells but the difference in expression levels between the WT and *MTA1* knockdown in the MCF7 cell line is marginal. Up regulation of this gene was observed in *Mta1*-KO and *MTA1-siRNA* knock down samples when compared to the wild type MEFs and MCF7cells respectively. Another candidate, early growth response protein 2 \[encoded by *Egr2*\] and its human homolog was found to follow similar trend in MEFs and MCF7 cell line with significant difference in expression levels when compared between wild type and *Mta1*-KO. Finally, *Phf17*, a known apoptosis promoter which may act as a renal tumor suppressor [@pone.0017135-Zhou1] is found to be down regulated in the *Mta1* knock out MEFs. As expected the expression pattern of all these candidates is in agreement with the above described microarray data. Together, the expression of these representative genes highlights the possible interplay between the tumor suppressors (*Aw551984*, *Egr2*), apoptotic protein *(Phf17)* and oncogene *(Mta1)*. The bar charts (7A, 7B, 7C) in [Figure 7](#pone-0017135-g007){ref-type="fig"} show the expression levels of these three genes from the RT-qPCR assay and the Affymetrix microarray data.

![RT-qPCR validation of the microarray data showing the differential regulation of the selected genes in the MEFs.\
The RNA extracted from the fibroblasts of the wild type (light blue bars) mice was used as the control and the treatments were *Mta1*-KO (red bars) & *Mta1*-KO/*Mta1(green bars)*. In the presence of *P53* relative mRNA levels of the genes *Aw551984*, *Egr2*, *Phf17* were compared in all the three samples. The relative mRNA levels from microarray for the same sample sets were plotted and compared with the RT-qPCR. As expected, opposite trends of expression were observed between the knock out and re-expression models. To validate the genes regulated by *Mta1* in the absence of *P53* relative mRNA levels were compared among the three samples wild type (light blue bars), *P53*-KO (dark blue bars) & *P53*-KO/*Mta1*(yellow bars) for the genes *Hmmr*, *Klf15*, *Rnf144a*.The relative mRNA levels from the microarray were plotted and compared with RT-qPCR. Opposite trends of expression were observed between the *P53*-KO and *P53*-KO/*Mta1* treatments when compared with the wild type sample.](pone.0017135.g007){#pone-0017135-g007}

We also selected candidate genes that are regulated by *Mta1*, in the absence of *P53*, from the microarray data and subjected them to the RT-qPCR validation. The relative expression levels of these genes in the controls and treatments are shown in the [Figure 7](#pone-0017135-g007){ref-type="fig"} (7D, 7E, 7F). The data clearly shows the agreement between the microarray and the RT-qPCR results. We have chosen *Rnf144a* which contains RING figure motif and established to have role in protein-DNA and protein-protein interactions. We found that *Rnf144a* was upregulated in the absence of *P53* and over expression of *Mta1*. Another selected candidate was *Hmmr*, which encodes Hyaluronan mediated motility receptor protein that is found to be expressed in the breast tissue. It is notable that the *Hmmr* gene was found to be down regulated in *P53*-KO, whereas it was up regulated in *P53*-KO/*MTA1* when compared with the WT. The third candidate gene, *Klf15* which encodes a protein called kruppel like factor-15 was found to be highly up-regulated in *P53*-KO MEFs where as it is only weakly up-regulated in *P53*-KO/*Mta1*, when compared with the wild type. The expression levels from the RT-qPCR assay and the Affymetrix microarray data are in perfect agreement for all the chosen candidates in MEFs ([Figure 7](#pone-0017135-g007){ref-type="fig"}).

RT-qPCR assays were also conducted with human homologs to validate the genes that were believed to be regulated by *Mta1* in MEFs. This step of validation is performed with the *Mta1* knock down (*Mta1* siRNA) in MCF7compared with the non-target control siRNA. Similar differential gene expression levels were observed among all the genes (*VWA5A*, *EGR2*, *RNF144A*, *KLF15*, *and HMMR*) which are similar to the microarray expression profile ([Figure 8](#pone-0017135-g008){ref-type="fig"}).

![RT-qPCR was performed using the RNA obtained from the wild type MCF-7 cells and MCF-7 cells transfected with the *MTA1*-siRNA.\
The differential regulation of the selected genes (*EGR2*, *HMMR*, *KLF15*, *RNF144A*, *and VWA5A*) was observed in agreement with the Microarray and the RT-QPCR in the MEFs.](pone.0017135.g008){#pone-0017135-g008}

Discussion {#s3}
==========

This study represents a complete genome wide screen for possible target genes of a transcriptional co regulator, *Mta1*. In addition to identifying "bona fide" *Mta1* target genes, the influence of *p53* on *Mta1* gene regulation and molecular function has also been analyzed extensively. Emerging literature on *Mta1* clearly establishes bidirectional interplay between the oncogene, MTA1 and the tumor suppressor, P53. Although *Mta1* was found to be a component of the Nucleosome Remodeling and Deacetylase (NuRD) complex, recent studies from our laboratory establishes the functions of MTA1 in DNA-damage response in a P53-dependent and -independent manner [@pone.0017135-Li2], [@pone.0017135-Li3], [@pone.0017135-Li5]. This raises the compelling question of how *P53* influences the gene regulation and overall function of MTA1. We attempted to address this question using microarray approach. The first goal of identifying "bona fide" *Mta1* targets have been achieved by initial comparison of genes regulated by *Mta1* wild type and the *Mta1* knockout. Subsequently, this set of genes was compared with the set identified from the comparative study of *Mta1* knock out vs. *Mta1* re-expressed in the knock out MEFs. The common genes identified from both comparisons reflect the *Mta1* "bona fide" targets ([Table 3](#pone-0017135-t003){ref-type="table"} and [Table S5](#pone.0017135.s006){ref-type="supplementary-material"}). To achieve the goal of defining oncogenic gene profile of *Mta1*, we have mimicked most cancer scenarios i.e. loss of *P53* and the over expression of oncogenes such as *Mta1* and compared *P53* knock out and *P53* knockout in which there was over expression of *Mta1* gene. Interestingly, the identified 266 genes ([Table 4](#pone-0017135-t004){ref-type="table"}) are mostly involved in DNA damage response. This is in agreement with the recently established *Mta1* function in DNA damage which is independent of *P53*. Together, these data further illustrate the possible genes that are regulated by *Mta1* "fail safe" mechanism which occurs due to loss of *P53*.

The gene ontology analysis again highlights the influence of *P53* on *Mta1* function. If *P53* is present, the targets regulated by *Mta1* play no remarkable role in the molecular functions such as catalytic activity or binding where as in the absence of *P53* about 39% of genes regulated by *Mta1* are involved in molecular functions, clearly indicating the influence of *P53* on *Mta1* gene regulation. Further extensive comparative analysis of all the data using IPA and networks reveals two distinct functional themes. In the presence of *P53*, the genes regulated by *Mta1* are mainly involved in the inflammatory response cancer and cellular movement. Whereas, in the absence of *P53* the genes regulated are predominantly related to cancer signaling reflecting the significance of *Mta1* in cancer. In agreement to the above mentioned observations, the top networks and pathways regulated by *Mta1* in the presence of *P53* appear to be antimicrobial response, inflammatory response and carbohydrate metabolism ([Figure 9](#pone-0017135-g009){ref-type="fig"}). For instance, most of the genes regulated by *Mta1* revolve around major complexes such as IRF7 (Interferon regulatory factor-7), which has been shown to play important role in the transcriptional activation of virus inducible cellular genes. In addition, as a part of innate antiviral immunity, the induction of systemic IFN takes place through IRF7 [@pone.0017135-Honda1]. Another gene, Immunity-related GTPases (*IRG*) that play an important role in defense against intracellular pathogens and NFĸB complex which has been well ascertained to be regulated by *Mta1* were also found in the network. In agreement with our data recent studies suggest *MTA1* regulating its target genes either by acting as a corepressor [@pone.0017135-Mazumdar1], [@pone.0017135-Molli1] or as transcriptional coactivator [@pone.0017135-Gururaj1], [@pone.0017135-Balasenthil1] via interacting with RNA polymerase II. Together, these findings raise the possibility that *Mta1* may play a significant role in protecting regulation of innate immune response by directly modulating several pathways including NF-κB signaling [@pone.0017135-Pakala1]. Our data further supports this notion and emphasizes the role of *Mta1* in inflammation.

![Gene network analysis shows that the genes regulated by *Mta1* in the presence of *P53* are involved in the networks associated with antimicrobial and inflammatory responses (statistically most significant network).\
When compared with the wild type MEFs, the genes that were up regulated in *Mta1* knockout MEFs are shown in red and the down regulated genes are shown in green. The network with the highest score from the IPA analysis was considered to be the most significant network and majority of the genes that were found in this network were up-regulated.](pone.0017135.g009){#pone-0017135-g009}

In contrast to that, in the absence of *P53*, *Mta1* target genes appear to be mainly involved in cancer and genetic disorders ([Figure 10](#pone-0017135-g010){ref-type="fig"}). For instance, many direct and indirect interactions were found with well studied cancer molecules such as Kirsten rat sarcoma viral oncogene homolog (KRAS) [@pone.0017135-Dunn1], [@pone.0017135-Normanno1], epidermal growth factor receptor (EGFR) [@pone.0017135-Bild1]--[@pone.0017135-Gong1] and vascular endothelial growth factor (VEGF) [@pone.0017135-Benest1], [@pone.0017135-Benson1] further highlighting the *P53*-independent central functions of *Mta1* in metastasis and cancer. Thus, MTA1 appears to be playing distinct molecular functions depending on the status of *P53*. In summary, our data presents complete gene profiling of *Mta1* in the presence and absence of *P53* representing a new resource and guide for future area of *Mta1* research which is unexplored but comprises several key elements that could be employed in the development of anticancer therapeutics and identification of novel functions of *Mta1*.

![The genes differentially regulated (*p*-value\<0.05 and fold change ≥±2.0) between the *P53* knock out and the *P53* knock out with *Mta1* over expressed MEFs (*Mta1* regulated genes independent of *P53*) were subjected to the network analysis and the most significant network found is associated with cancer and genetic disorders.\
Most of the genes in the network were found to be down regulated in *P53*-KO/*Mta1* when compared with *P53*-KO. All the upregulated genes are shown in red and the down regulated genes are shown in green color.](pone.0017135.g010){#pone-0017135-g010}

Materials and Methods {#s4}
=====================

Cell Culture {#s4a}
------------

Wild type Murine Embryonic Fibroblasts (MEFs) and *Mta1*-KO MEFs were obtained as described previously [@pone.0017135-Manavathi2]. *P53* knock out MEFs were kindly provided by Dr. G. Lozano (M.D. Anderson Cancer Center, Houston, TX). MEFs and MCF7 (Michigan Cancer Foundation-7 human breast cancer cell line) were cultured in DMEM/F-12 medium containing 10% fetal bovine serum (FBS-Difco Laboratories, Detroit, Michigan) and 1% antibiotic-antimycotic solution in a humidified 5% CO~2~ at 37°C. Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). *Mta1^+/+^*, *Mta1^−/−^*, *Mta1^−/−^/Mta1*, *p53^−/−^ and p53^−/−^/Mta1* MEFs have been described previously [@pone.0017135-Li1], [@pone.0017135-Li2]. Human MTA1 and non target control siRNA smart pools were obtained from Dharmacon, Inc. MCF7 cells were obtained from ATCC (ATCC number: HTB-22) Transfection into MCF7 cells was performed with Oligofectamine reagent (Invitrogen) and manufacturer\'s instructions were followed. Cells were collected after 36--48 hours after transfection.

RNA Extraction & Microarray Gene Expression Arrays {#s4b}
--------------------------------------------------

Microarray gene expression assays have been performed as described previously [@pone.0017135-Li3]. In summary total RNA was extracted from the cells using Trizol (Invitrogen, Carlsbad, CA) and the manufacturer\'s protocol was followed. The quality and the concentrations of the extracted RNA were checked using the Nano-Drop (Thermo scientific). RNA was then purified using RNeasy Mini Kit (Qiagen, Valencia, CA) and the integrity was tested on 6000 NanoChips using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Finally, Affymetrix Mouse Exon 1.0 ST arrays were used for the hybridization, arrays were scanned and the expression data was obtained in the form of .CEL files.

Microarray data analysis {#s4c}
------------------------

To analyze the data generated from the microarray experiments we used GeneSpring GX 10.0.2 (Agilent technologies, Inc) software package for the data Quality Control and the statistical analysis of the microarray data. The method of Benjamini and Hochberg was applied for the multiple corrections with a *p*-value cut-off of 0.05 and fold change ≥±2.0 to obtain the statistically significant genes. Heat maps for individual arrays were generated and the hierarchical cluster analysis was performed using MeV 4.5 [@pone.0017135-Saeed1]. Gene Ontology analysis was performed using GeneSpring GX 10.0.2 (Agilent Technologies). All data is MIAME compliant and the raw data has been deposited in Gene Expression Omnibus (GEO) as detailed on the Microarray Gene expression Data Society (MGED) society website (<http://www.mged.org/Workgroups/MIAME/miame.html>).

Functional and Network Analysis {#s4d}
-------------------------------

We used the Ingenuity pathway Analysis (Ingenuity Systems, Inc) to find the statistically significant pathways, functions and the networks in which the identified genes regulated by *Mta1*are possibly involved. Fischer\'s exact test was used to identify the significant functions and pathways represented within the respective gene sets.

RT-qPCR {#s4e}
-------

RT-qPCR analysis was performed following the protocol described previously [@pone.0017135-Li1], [@pone.0017135-Li2]. In order to validate the microarray data we selected candidate genes and RT-qPCR assays were conducted (all the primers used in this study are listed in [Table S10](#pone.0017135.s011){ref-type="supplementary-material"}). 2 µg of the total RNA was used for the first strand cDNA synthesis using the superscript III First-strand sys kit (Invitrogen), according to the manufacturer\'s instructions in 21-µl reactions. These reactions were diluted 1∶10 with nuclease-free water. Duplicates of the qPCR contained 2-µl of the first strand cDNA, 1-µl of the intron-spanning primers specific for that particular mRNA sample, 2 µl of nuclease free water and 5 µl of SYBR Green (Bio-Rad, Hercules, CA). Reactions (10 µl) were run in 96-well optical plates (Bio-Rad, Hercules, CA). Average threshold cycle (Ct) values of 18S mRNA (chosen as normalizer) were subtracted from the corresponding average Ct values of a target mRNA to obtain ΔCt values. The relative RNA levels were then expressed as 2^−Δct^.

Supporting Information {#s5}
======================

###### 

Western blot assay of the five samples (WT, Mta1-KO, Mta1-KO/Mta1, P53-KO, and P53-KO/Mta1) was performed using Mta1 antibody as described previously [@pone.0017135-Li3] and the levels of Mta1 in all the five conditions are shown. α-Tubulin was used as the internal control.

(TIF)

###### 

Click here for additional data file.

###### 

Complete list of the differentially expressed probe sets on the Affymetrix Mouse Exon 1.0 ST arrays between the wild type and the *Mta1* knock out MEFs.

(XLS)

###### 

Click here for additional data file.

###### 

The statistical summary of the log 2 ratio values for the differentially expressed probe sets on the Affymetrix Mouse Exon 1.0 ST arrays between the wild type and the *Mta1* knock out MEFs.

(DOC)

###### 

Click here for additional data file.

###### 

Complete list of the differentially expressed probe sets on the Affymetrix Mouse Exon 1.0 ST arrays between the *Mta1* knockout (*Mta1*-KO) MEFs and *Mta1* reintroduced into the knock out MEFs (*Mta1*-KO/*Mta1*).

(XLS)

###### 

Click here for additional data file.

###### 

The statistical summary of the log 2 ratio values for the differentially expressed probe sets on the Affymetrix Mouse Exon 1.0 ST arrays between the *Mta1* knockout (*Mta1*-KO) MEFs and *Mta1* reintroduced into the knock out MEFs (*Mta1*-KO/*Mta1*).

(DOC)

###### 

Click here for additional data file.

###### 

The 'Bona fide' genes that are regulated by *Mta1*.

(DOC)

###### 

Click here for additional data file.

###### 

Complete list of the differentially expressed probe sets on the Affymetrix Mouse Exon 1.0 ST arrays between the *P53* knock out (*P53*-KO) and *P53* knockout MEFs with over expression of *Mta1*(*P53*-KO/*Mta1*).

(XLS)

###### 

Click here for additional data file.

###### 

The statistical summary of the log 2 ratio values for the differentially expressed probe sets on the Affymetrix Mouse Exon 1.0 ST arrays in MEFs between the *P53* knockout (*P53*-KO) and *P53* knockout MEFs with over expression of *Mta1* (*P53*-KO/*Mta1*).

(DOC)

###### 

Click here for additional data file.

###### 

Gene Ontology analysis of the genes differentially regulated between WT & *Mta1*-KO with ≥2.0 fold change.

(DOC)

###### 

Click here for additional data file.

###### 

Gene Ontology analysis of the 'bona fide' *Mta1* regulated genes in the absence of *P53* with ≥2.0 fold change.

(DOC)

###### 

Click here for additional data file.

###### 

Primer sequences for the candidate genes of *Mus Musculus* and *Homo sapiens* that were used in the RT-qPCR assays are shown.

(DOC)

###### 

Click here for additional data file.
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